Dilaforette is Granted SEK 2.8M for Development of Sevuparin for the Treatment of Severe Malaria

November 2, 2012 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

STOCKHOLM – November 2, 2012. Dilaforette announces today that it has been granted SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.

Twitter
LinkedIn
Facebook
Email
Print

Europe